Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab

Neoplasia (United States)

Volumn 15, Issue 10, 2013, Pages 1196-1206

  Iida, Mari ^a   Brand, Toni M ^a   Starr, Megan M ^a   Li, Chunrong ^a   Huppert, Evan J ^a   Luthar, Neha ^a   Pedersen, Mikkel W ^b   Horak, Ivan D ^b   Kragh, Michael ^b   Wheeler, Deric L ^a  

^a University of Wisconsin Health   (United States)

^b Symphogen AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE 3; CETUXIMAB; FUTUXIMAB; IMMUNOGLOBULIN G; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84887118578     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131584     Document Type: Article

References (40)

1. Wheeler DL, Dunn EF, and Harari PM (2010). Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493-507.
2. Yarden Y and Pines G (2012). The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12, 553-563.
3. Sebolt-Leopold JS and Herrera R (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4, 937-947.
4. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, and Ferguson KM (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301-311.
5. Martinelli E, De Palma R, Orditura M, De Vita F, and Ciardiello F (2009). Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158, 1-9.
6. Brand TM, Iida M, and Wheeler DL (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11, 777-792.
7. Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, and Wheeler DL (2011). Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther 12, 436-446.
8. Li C, Iida M, Dunn EF, Ghia AJ, and Wheeler DL (2009). Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801-3813.
9. Li C, Iida M, Dunn EF, and Wheeler DL (2010). Dasatinib blocks cetuximaband radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 97, 330-337.
10. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, and Harari PM (2008). Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944-3956.
11. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, and Harari PM (2009). Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8, 696-703.
12. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, and Roovers RC (2009). Crosstalk between epidermal growth factor receptorand insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 9, 748-760.
13. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, and Rosmorduc O (2009). Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15, 5445-5456.
14. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, and Harari PM (2009). Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15, 1585-1592.
15. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, and Kragh M (2010). Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70, 588-597.
16. Koefoed K, Steinaa L, Søderberg JN, Kjæer I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, et al. (2011). Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. mAbs 3, 584-595.
17. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, et al. (2007). Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13, 1552-1561.
18. Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, et al. (2012). Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. Neoplasia 14, 190-205.
19. Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, and Pèlegrin A (2012). In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia 14, 121-130.
20. Iida M, Brand TM, Campbell DA, Li C, and Wheeler DL (2013). Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 32, 759-767.
21. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. (2007). Cetuximab for the treatment of colorectal cancer. N Engl J Med 357, 2040-2048.
22. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, and Baselga J (2007). Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25, 2171-2177.
23. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531.
24. Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, Daniele G, Giordano P, Bryce J, Normanno N, et al. (2012). Cetuximab in non-small-cell lung cancer. Expert Rev Anticancer Ther 12, 163-175.
25. Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, and Binder M (2012). Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 14, 1023-1031.
26. Graham J, Muhsin M, and Kirkpatrick P (2004). Cetuximab. Nat Rev Drug Discov 3, 549-550.
27. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A, and Werner JA (2006). Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580, 4793-4800.
28. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, et al. (2008). Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14, 5069-5080.
29. Kim SM, Kim JS, Kim JH, Yun CO, Kim EM, Kim HK, Solca F, Choi SY, and Cho BC (2010). Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 296, 150-159.
30. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, et al. (2010). Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximabresistance in head and neck squamous cell carcinoma. PLoS One 5, e12702.
31. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, et al. (2011). Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancerresistant protein expression in gefitinib-resistant cells. J Biol Chem 286, 20558-20568.
32. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, and Rodemann HP (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280, 31182-31189.
33. + channels. Radiother Oncol 101, 122-126.
34. Hsu SC, Miller SA, Wang Y, and Hung MC (2009). Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 1, 249-258.
35. Liccardi G, Hartley JA, and Hochhauser D (2011). EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 71, 1103-1114.
36. Anjum R and Blenis J (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9, 747-758.
37. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. (2012). Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18, 221-223.
38. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, and Wheeler DL (2011). Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30, 561-574.
39. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820.
40. Dienstmann R (2011). Phase I trial of the first-in-class EGFR mAb mixture, Sym004, in patients with refractory advanced solid tumors. In JCO, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 29(15 suppl.), 3089.